NewAmsterdam Pharma (NAMS) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for NewAmsterdam Pharma (NASDAQ: NAMS):

• 7/20/2026 – NewAmsterdam Pharma is now covered by BMO Capital Markets. They set an “outperform” rating and a $58.00 price target on the stock.
• 7/20/2026 – NewAmsterdam Pharma had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $45.00 price target on the stock.
• 7/20/2026 – NewAmsterdam Pharma was upgraded by BMO Capital Markets to “strong-buy”.
• 7/17/2026 – NewAmsterdam Pharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/30/2026 – NewAmsterdam Pharma had its price target raised by Royal Bank Of Canada from $47.00 to $51.00. They now have an “outperform” rating on the stock.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 105,000 shares of the firm’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $738,870.02. This trade represents a 81.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 210,000 shares of company stock worth $6,713,550 over the last three months. Company insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.